KRRO Korro Bio Inc.

Price (delayed)

$41.91

Market cap

$30.95M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$83

Enterprise value

-$11.31M

frequency therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. through the controlled activation of progenitor cells, frequency enables disease modification without the ...

Highlights

Korro Bio's debt has plunged by 97% YoY and by 95% from the previous quarter

KRRO's EPS is up by 33% YoY and by 13% QoQ

Korro Bio's equity has plunged by 55% YoY and by 19% from the previous quarter

KRRO's quick ratio is down by 22% since the previous quarter and by 10% year-on-year

Sector: Healthcare

Industry: Biotechnology

Website: http://frequencytx.com

Key stats

What are the main financial stats of KRRO

Market

Shares outstanding

738,526

Market cap

$30.95M

Enterprise value

-$11.31M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

0.83

Price to sales (P/S)

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

Earnings

Revenue

EBIT

-$60.46M

EBITDA

-$55.4M

Free cash flow

-$43.02M

Per share

EPS

-$83

Free cash flow per share

-$58.25

Book value per share

$50.3

Revenue per share

TBVPS

$62.77

Balance sheet

Total assets

$46.35M

Total liabilities

$9.61M

Debt

$1.43M

Equity

$36.74M

Working capital

$32.89M

Liquidity

Debt to equity

0.04

Current ratio

4.42

Quick ratio

4.55

Net debt/EBITDA

0.76

Margins

EBITDA margin

N/A

Gross margin

N/A

Net margin

N/A

Operating margin

N/A

Efficiency

Return on assets

-68.1%

Return on equity

-116%

Return on invested capital

-110.9%

Return on capital employed

-164.6%

Return on sales

N/A

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

KRRO stock price

How has the Korro Bio stock price performed over time

Intraday

4.31%

1 week

10.64%

1 month

19,257.97%

1 year

1,787.84%

YTD

988.57%

QTD

11,227.03%

Financial performance

How have Korro Bio's revenue and profit performed over time

Revenue

Gross profit

Operating income

-$63.2M

Net income

-$59.32M

Gross margin

N/A

Net margin

N/A

KRRO's net income is up by 31% year-on-year and by 12% since the previous quarter

KRRO's operating income is up by 27% year-on-year and by 11% since the previous quarter

Growth

What is Korro Bio's growth rate over time

Valuation

What is Korro Bio stock price valuation

P/E

N/A

P/B

0.83

P/S

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

KRRO's EPS is up by 33% YoY and by 13% QoQ

The stock's price to book (P/B) is 59% less than its 5-year quarterly average of 2.0 but 19% more than its last 4 quarters average of 0.7

Korro Bio's equity has plunged by 55% YoY and by 19% from the previous quarter

Efficiency

How efficient is Korro Bio business performance

KRRO's ROIC has plunged by 72% YoY and by 38% from the previous quarter

The return on equity has declined by 43% year-on-year and by 8% since the previous quarter

KRRO's return on assets is down by 26% year-on-year and by 11% since the previous quarter

Dividends

What is KRRO's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for KRRO.

Financial health

How did Korro Bio financials performed over time

KRRO's total liabilities has shrunk by 82% YoY and by 72% QoQ

The total assets has dropped by 66% year-on-year and by 42% since the previous quarter

Korro Bio's debt is 96% less than its equity

Korro Bio's debt has plunged by 97% YoY and by 95% from the previous quarter

KRRO's debt to equity has dropped by 93% since the previous quarter and by 93% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.